Comparative Pharmacology
Head-to-head clinical analysis: PENTIDS 250 versus PIPERACILLIN TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTIDS 250 versus PIPERACILLIN TAZOBACTAM.
PENTIDS '250' vs Piperacillin-Tazobactam
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
250 mg orally every 8 hours.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
None Documented
None Documented
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic + Beta-Lactamase Inhibitor